Cytokinetics Inc (NASDAQ: CYTK) is 6.85% higher on its value in year-to-date trading and has touched a low of $40.53 and a high of $81.36 in the current 52-week trading range. The question becomes, what are the chances the stock will continue to grow shareholders’ wealth in the market. Here’s what analysts think will happen to its price in the coming time. The CYTK stock was last observed hovering at around $51.12 in the last trading session, with the day’s loss setting it -0.86%.
Currently trading at $50.26, the stock is 6.78% and 5.57% above its SMA20 and SMA50 respectively. However, with a daily trading volume of 2.17 million and changing -1.68% at the moment leaves the stock -5.05% off its SMA200. CYTK registered -34.63% loss for a year compared to 6-month loss of -11.59%.
The stock witnessed a 7.35% gain in the last 1 month and extending the period to 3 months gives it a -3.23%, and is 20.76% up over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 8.24% over the week and 5.95% over the month.
Cytokinetics Inc (CYTK) has around 423 employees, a market worth around $5.93B and $3.22M in sales. Profit margin for the company is -17906.24%. Distance from 52-week low is 24.01% and -38.23% from its 52-week high. The company has generated returns on investments over the last 12 months (-77.33%).
with sales reaching $14.26M over the same period.The EPS is expected to grow by 4.86% this year, but quarterly earnings will post 90.85% year-over-year. Quarterly sales are estimated to grow 752.98% in year-over-year returns.
Cytokinetics Inc (CYTK) Top Institutional Holders
The shares outstanding are 117.89M, and float is at 114.52M with Short Float at 11.92%.
The top institutional shareholder in the company is BLACKROCK INC. with over 14.67 million shares valued at $794.97 million. The investor’s holdings represent 14.3958% of the CYTK Shares outstanding. As of 2024-06-30, the second largest holder is FMR LLC with 11.52 million shares valued at $$624.32 million to account for 11.3056 of the shares outstanding. The other top investors are VANGUARD GROUP INC which holds 11.44 million shares representing 11.2218% and valued at over $619.69 million, while T. ROWE PRICE INVESTMENT MANAGEMENT, INC. holds 7.4503 of the shares totaling 8.14 million with a market value of $440.95 million.
Cytokinetics Inc (CYTK) Insider Activity
The most recent transaction is an insider sale by Malik Fady Ibraham,the company’sEVP Research & Development. SEC filings show that Malik Fady Ibraham sold 2,000 shares of the company’s common stock on Feb 18 ’25 at a price of $45.98 per share for a total of $91960.0. Following the sale, the insider now owns 0.12 million shares.
Cytokinetics Inc disclosed in a document filed with the SEC on Feb 04 ’25 that Malik Fady Ibraham (EVP Research & Development) sold a total of 2,000 shares of the company’s common stock. The trade occurred on Feb 04 ’25 and was made at $48.06 per share for $96120.0. Following the transaction, the insider now directly holds 0.12 million shares of the CYTK stock.
Still, SEC filings show that on Jan 21 ’25, Malik Fady Ibraham (EVP Research & Development) disposed off 2,000 shares at an average price of $45.92 for $91840.0. The insider now directly holds 116,071 shares of Cytokinetics Inc (CYTK).
